Aryl hydrocarbons (AHs) such as 2,3,7,8-tetrachlorodibenzo-p-dioxin and benzo[a]pyrene activate the sequence-specific DNA-binding activity of the AH receptor. In the rat hepatocyte-derived cell line LCS7, DNA-binding activity peaked after 30 min and was then down-regulated, reaching negligible levels by 2 h. Down-regulation could be blocked, and DNA-binding activity maintained at maximum for many hours by inhibiting protein or RNA synthesis, implying that down-regulation is a mediated process requiring a labile or inducible protein. CYPIAJ transcription and in vivo DNA-protein interactions at xenobiotic response elements were down-regulated in parallel with DNA-binding activity in nuclear extracts, and these changes could also be blocked by inhibitors of protein synthesis. The correlation between AH receptor DNA-binding activity, intensity of in vivo footprints at xenobiotic response elements, and CYPIAl transcription rate implies that down-regulation of AH receptor DNA-binding activity is important in regulating CYPIA1 transcription and that receptor is required continuously to maintain transcription. This correlation extends to the murine hepatoma cell line Hepa-lclc7, in which slower kinetics of activation and down-regulation of CYPIA1 transcription paralleled slower activation and down-regulation of AH receptor DNA-binding activity. The difference in kinetics between cell lines also implies that AH receptor DNA-binding activity is modulated by a mechanism that may be influenced by cell-specific regulatory pathways. The above observations in conjunction with mixing experiments and comparisons of cytoplasmic and nuclear extracts indicate that down-regulation of AH receptor DNA-binding activity is probably due either to degradation or to conversion of the receptor to a form that is inactive in both DNA binding and transactivation.
The aryl hydrocarbon (AH) receptor (34, 43, 53 ) is the prototype of a newly identified family of nuclear receptors (4, 10, 23, 38) , which is distinct both structurally and functionally from the steroid/thyroid receptor superfamily of nuclear receptors. The AH receptor is heteromeric, consisting of at least two distinct gene products, the AH receptor protein (AHR) (4, 10) , which displays ligand-binding function, and the AH receptor nuclear translocator protein (ARNT) (23, 38) . Both belong to a family of proteins that share a 200-bp region of high sequence similarity, termed the PAS region (for Per, ARNT, and Sim) (27) . They also belong to a wider family of heterodimeric transcription regulatory factors that contain the basic helix-loop-helix motif (3, 50) .
As a ligand-activated transcription factor, the AH receptor activates the transcription of a large number of genes (18, 28) . CYPlAl, the gene encoding cytochrome P4501A1, is the most thoroughly studied of these and is therefore a useful model system for investigating this receptor. Regulation of this gene is also of fundamental importance in carcinogenesis and in drug metabolism and other detoxification reactions, since P4501A1 carries out the mixed-function oxidation, not only of many endogenous compounds, such as 1713-estradiol, but also of xenobiotics, including drugs, dietary components, mutagens, carcinogens, and environmental pollutants such as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and benzo [a] pyrene (17, 31) .
In the absence of ligand, the AHR is located in the cytosol in association with the 90-kDa heat shock protein, hsp9O (32, 35, 54) . Exposure to AH ligands brings about a complex sequence of events, including binding of ligand to the AHR, dissociation of hsp90, translocation of AHR to the nucleus, association with ARNT, and activation of sequence-specific DNA-binding activity (10, 15, 22, 23, 38, 52) . Finally, the nuclear AH receptor complex activates transcription when bound to xenobiotic response elements (XREs) upstream of CYPlAl (13, 14, 19, 29, 44, 51) .
Here we present evidence that subsequent to this series of events, AH receptor DNA-binding activity is down-regulated and that down-regulation is mediated by a labile or inducible protein, since it can be blocked by inhibitors of protein and RNA synthesis. We also provide evidence that this downregulation is of significance to regulation of CYPlAl transcription. First, CYPJAl transcription, as well as in vivo interaction of the receptor at XREs, is down-regulated in parallel with in vitro DNA-binding activity, but with somewhat slower kinetics. Second, the kinetics and extent of down-regulation do not follow a fixed pattern Nuclear extracts and EMSA. Cell culture, preparation of nuclear extracts from LCS7 and Hepa-lclc7 (Hepa-1) cells, and EMSA of sequence-specific DNA-binding activity were carried out as described previously (41) . The preparation and labeling of oligonucleotide probes used in EMSA and the sequence of the XRE1 oligonucleotide have been described elsewhere (41) . The sequence of the upper strand of the Sp-1 oligonucleotide was 5'-GATCCAGACCCCGCCCACTA-3'.
In vivo footprinting. Rat hepatocyte-derived LCS7 cells, a clonal derivative of RALA255-qpG (6, 7), were grown to confluence in 120-mm-diameter tissue culture dishes as previously described (41) . Cells were treated with 1 nM TCDD in dimethyl sulfoxide for 30, 60, 120, and 240 min prior to dimethyl sulfate treatment. Cycloheximide was added 30 min prior to treatment with TCDD. Dimethyl sulfate treatment, DNA extraction, piperidine treatment of DNA, and ligationmediated PCR were performed as described previously (26, 40) . Labeled products were resolved on denaturing 6% polyacrylamide gels.
Nuclear run-on transcription. Nuclei were isolated, and nuclear RNA was elongated in vitro (2 x 107 nuclei per reaction) and purified as described previously (30) 5 ,ug/ml) for 0 to 120 min as specified (NT, no treatment). Cells were harvested, nuclear extracts were prepared, and specific binding to 32P-labeled XRE1 was measured by EMSA. (B) Cells were treated with f3-naphthoflavone and/or cycloheximide (10 ,ug/ml) or actinomycin D (5 .Lg/ml) for the times (in minutes) specified.
(C) Cytosolic extracts from LCS7 cells treated with P-naphthoflavone and/or cycloheximide for the given times (in minutes) were activated, and XRE1-binding activity of the receptor was measured by EMSA. R, AH receptor DNA complex; F, free probe. (8, 9, 14, 21, 42) as well as in the rat hepatocyte-derived cell line LCS7 (41, 42) . The experiment presented in Fig. IA (Fig. 2A ). Protection at a single guanine on the other strand paralleled these changes (Fig. 2B) . Thus, the appearance and disappearance of in vivo footprints were parallel to the induction and down-regulation of AH receptor DNA-binding activity but lagged by about 30 min. TCDD induced similar footprints with identical kinetics at XRE2 and XRE3 (data not shown), and these footprints were consistent with previous reports (40, 48, 49, 55, 56) .
As shown in Fig. 2C Fig. 1 and 2 . As in the gel shift and the footprinting experiments, treatment with TCDD alone caused an initial increase in CYPlAl transcription that reached maximum 1 h after exposure to TCDD (Fig. 3, lane 4) . Subse Since activation of AH receptor to a DNA-binding form involves translocation from the cytoplasm to the nucleus, we explored the possibility that down-regulation involves the reciprocal movement of receptor from the nucleus to the cytoplasm. We prepared cytoplasmic and nuclear extracts from LCS7 cells treated for different time periods either with ,B-naphthoflavone alone or with P-naphthoflavone plus cycloheximide. After activating the cryptic AH receptor DNAbinding activity in the cytoplasmic extracts, we analyzed all extracts for AH receptor DNA-binding activity by EMSA. In cells treated with inducer, AH receptor DNA-binding activity disappeared from the cytoplasmic fraction and appeared in nuclear extracts (Fig. 1B and C, lanes 2 and 3) . This movement between cytoplasm and nucleus was, however, not reversed during down-regulation; disappearance of receptor from the nucleus was not accompanied by reappearance of receptor in cytoplasmic extracts (compare lanes 4 of Fig. 1B and C) . Thus, during down-regulation, the receptor must be either degraded or converted into a form that does not bind DNA.
The kinetics of both activation and down-regulation of the AH receptor are slower in Hepa-1 cells than in LCS7 cells. Receptor activation in Hepa-1 cells peaked after about 1 h (Fig. 4A, lane 2) , compared with 30 min in LCS7 cells (Fig.  1A) , and receptor down-regulation was also more gradual. Furthermore, in Hepa-1 cells, AH receptor DNA-binding activity did not fall to undetectable levels, as it did in LCS7 cells, but remained at a low but significant level for many hours. By 7 h after exposure to inducer, AH receptor levels had fallen substantially, but this level of activity remained in nearly steady state thereafter ( Fig. 4A; compare lanes 2, 6, and 9 ). Cycloheximide acted similarly in LCS7 and Hepa-1 cells, preventing down-regulation of AH receptor DNA-binding activity (compare lanes 6 with 7 and lanes 9 with 11). Because down-regulation was slow and incomplete in Hepa-1 cells, it was possible to block the down-regulation process with the addition of cycloheximide hours after addition of TCDD. (lane 6) . Because of the more rapid kinetics of down-regulation in LCS7 cells, the ability of cycloheximide to prevent down-regulation could be observed conveniently only when cycloheximide was added simultaneously with TCDD (Fig. 1) . Figure 4B shows that Sp-1-binding activity was relatively invariant in all nuclear extracts, indicating that the changes observed in AH receptor levels were not the result of extract variability.
The run-on transcription experiment in Fig. 5 shows that in parallel with XRE-binding activity, CYPlAl transcription rate increased more slowly in Hepa-1 cells than in LCS7 cells, peaking between 1 and 2 h after exposure to TCDD. Interestingly, whereas the transcription rate in LCS7 cells dropped to basal levels at later times, that in Hepa-1 cells treated with TCDD remained high at 2 and 4 h (Fig. 5, lanes 6 and 8) , even though AH receptor DNA-binding activity, measured in vitro, dropped markedly (Fig. 4A) . At any time during that period, addition of cycloheximide could superinduce transcription in Hepa-1 cells (25) An EMSA comparing cytoplasmic and nuclear extracts from LCS7 cells showed that during activation, the cytoplasmic form of the receptor disappears as the nuclear form begins to appear. However, during down-regulation, the reverse was not observed; receptor did not reappear in the cytoplasm as nuclear receptor disappeared. This finding indicates that down-regulation is not a process in which the receptor is cycled from the nucleus back to the cytoplasm. (iii) The previously published half-life of the cytosolic AH receptor (45) is considerably longer than the time it takes to downregulate the nuclear receptor maximally in Hepa-1 cells. This eliminates the possibility that down-regulation of the nuclear receptor proceeds by the same mechanism that determines the half-life of the cytoplasmic receptor. It is worth noting, however, that our observations regarding down-regulation of the DNA-binding and transactivation functions of the nuclear AH receptor are consistent with earlier observations of downregulation of AH receptor ligand-binding activity (36) . (iv) An additional possibility is eliminated when in vivo footprinting and run-on transcription data are considered. Because in vivo footprints and CYPIA1 transcription are down-regulated in parallel with AH receptor DNA-binding activity, it is unlikely that unextractable but functional receptor could still be bound to XREs in the nucleus at that time. Thus, if an unextractable form of the receptor is present in the nucleus, this form must also lack the ability to transactivate. With these possibilities eliminated, we conclude that during down-regulation, the AH receptor is either degraded or converted to a form that lacks both DNA-binding activity and transactivating function. We know that a labile protein is involved in this process. It could down-regulate the receptor through either covalent modifications or direct associations. Down-regulation is not likely due to stable association of another protein with the AH receptor, since the electrophoretic mobility of the receptor isolated from cells treated with TCDD alone is indistinguishable from the mobility of receptor from cells treated with both TCDD and cycloheximide. Thus, the labile protein may influence the receptor through less stable associations or through covalent modifications. Especially in light of evidence that protein kinases are involved in AH receptor activation (2, 5) , it will be worthwhile to investigate a possible role for dephosphorylation in down-regulation.
Ongoing CYPIAl transcription requires the continuous presence of AH receptor. It is well established that the AH receptor is required for induction of CYPJAl by AHs (18, 53) . However, the molecular mechanism of receptor action is not fully understood. The observation that CYPlAl transcription rate falls off in parallel with disappearance of AH receptor DNA-binding activity, measured in vitro by EMSA and in vivo by ligation-mediated PCR footprinting, sheds light on one facet of that mechanism. It implies that the AH receptor must be present continuously in order to maintain CYPJAl transcription and that the AH receptor complex probably does not activate CYPlAl transcription by a hit-and-run mechanism, as has been proposed for the glucocorticoid receptor (1, 39 Although the continuous presence of receptor is required to maintain transcription, the level of nuclear AH receptor DNA-binding activity required to establish and maintain full activation of CYPIA1 transcription and to establish and maintain maximal occupation of XREs, as detected by in vivo footprinting, seems to be much less than the maximum level of binding activity observed by EMSA. This can be concluded from the finding that in Hepa-1 cells, transcription remained at maximum levels (Fig. 5 ) and in vivo footprints remained at maximal intensity (56) even after AH receptor DNA-binding activity, measured by EMSA, had been down-regulated to a large degree (Fig. 4) (25) . At that time, we observe that AH receptor DNA-binding activity is down-regulated to low, residual levels (Fig. 4A) . Even (Fig. 1A) . These (46) , and with primary cultures of adult rat hepatocytes, which behave similarly to Hepa-1 cells (37) . The (25, 42) indicates that superinduction requires only XREs and a minimal heterologous promoter. Thus, superinduction must be mediated through proteins that interact with XREs. Earlier evidence (42) implicated a cycloheximide-sensitive XRE-binding protein other than the AH receptor, and a role for such factors has been reported for other cell types (20, 33) . However, current evidence suggests that this is probably not the case for hepatocyte-derived cell lines (24, 25 Finally, off-rate experiments, comparing nuclear extracts from cells treated with TCDD and TCDD plus cycloheximide, indicated that the affinities of the AH receptor for XREs were identical in nuclear extracts from induced and superinduced cells. We conclude that superinduction must alter the ability of the receptor to activate transcription without altering its affinity for, or interactions with, XREs. Thus, the receptor may exist in two transactivating forms that are interconvertible by a labile or inducible factor. These would be indistinguishable in terms of XRE-binding properties but would differ in the ability to transactivate, one inducing and the other superinducing CYPlAl transcription. For instance, one form of the AH receptor complex might include a labile protein that partially represses its ability to activate transcription. In the presence of cycloheximide, this protein would be lost, yielding a second form with increased activity. Alternatively, one form of the receptor could be covalently modified (e.g., by phosphorylation) and the labile protein could reverse that modification, converting it to a form with reduced activity. Since treatment with cycloheximide results in both superinduction and the blocking of AH receptor down-regulation, it is possible that a single cycloheximide-sensitive alteration of the AH receptor is responsible for both partially repressing the ability of the receptor to activate transcription and predisposing it to downregulation.
